NRAS mutation

Activating NRAS mutations detected by sequencing or PCR; used as a predictive marker in colorectal cancer (anti-EGFR antibodies) and studied in melanoma.

CI-BIO-00000017NRAS graph →NCIt C41381 Tumor-agnostic · 4 approval rows

Also calledNRAS-mutant · NRAS-mutated

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (13)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	17	16	1	—	1 / 6 / 8 / 2 / 0
Melanoma	15	12	2	1	0 / 6 / 6 / 3 / 0
Cutaneous Melanoma	9	9	—	—

Derived

Drugs with predictive evidence (20)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
CetuximabMonoclonal Antibody	14	—	14	A	0 / 13	Malignant Colorectal Neoplasm
BinimetinibSmall Molecule	8	8	—	B	7 / 0	Cutaneous Melanoma, Melanoma, Neuroblastoma, Solid Neoplasm
TrametinibSmall Molecule	6	6	—	B	5 / 0	Cutaneous Melanoma, Lung Non-Small Cell Carcinoma, Malignant Neoplasm, Malignant Ovarian Serous Tumor +1
SelumetinibSmall Molecule	6	6	—	B	4 / 0	Cutaneous Melanoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm
BelvarafenibSmall Molecule	5	5	—	C	5 / 0	Acral Lentiginous Melanoma, Melanoma, Mucosal Melanoma
Chemotherapy	4	—	4	B	0 / 4	Malignant Colorectal Neoplasm
IrinotecanSmall Molecule	4	—	4	C	0 / 4	Malignant Colorectal Neoplasm
VemurafenibSmall Molecule	3	—	3	B	0 / 3	Cutaneous Melanoma, Melanoma
PanitumumabMonoclonal Antibody	2	—	2	A	0 / 2	Malignant Colorectal Neoplasm
TemozolomideSmall Molecule	2	2	—	C	2 / 0	Melanoma
AmuvatinibSmall Molecule	1	1	—	D	1 / 0	Cutaneous Melanoma
DabrafenibSmall Molecule	1	—	1	B	0 / 1	Melanoma
DactolisibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
DocetaxelSmall Molecule	1	1	—	B	1 / 0	Cutaneous Melanoma
EverolimusSmall Molecule	1	1	—	D	1 / 0	Neuroblastoma
MetforminSmall Molecule	1	1	—	D	1 / 0	Malignant Neoplasm
OmipalisibSmall Molecule	1	1	—	D	1 / 0	Melanoma
RibociclibSmall Molecule	1	1	—	B	1 / 0	Cutaneous Melanoma
TanespimycinSmall Molecule	1	1	—	C	1 / 0	Melanoma
MEK Inhibitor RO4987655	1	—	1	C	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (47)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–47 of 47 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NRAS G13R3
Belvarafenib	Acral Lentiginous Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID13214 A patient with acral melanoma harboring NRAS G13R received belvarafenib monotherapy after four prior lines of systemic therapy and achieved stable disease as the best RECIST response. The patient rece… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic
Cetuximab + IrinotecanCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	1	accepted	EID2204 One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
Panitumumab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	1	accepted	EID3842 One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G13R, was wildtype for KRAS, BRAF and PIK3CA… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
NRAS Q61K8
Belvarafenib	Acral Lentiginous Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID13218 A patient with acral melanoma harboring NRAS Q61K received belvarafenib as first-line therapy for metastatic disease after progression on adjuvant pembrolizumab and achieved stable disease as the best… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic
Selumetinib	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID1475 Preclinical study in melanoma cell lines. NRAS Q61K, in addition to the BRAF V600E mutation was associated with resistance to vemurafenib but sensitivity to AZD6244 (selumetinib) in vitro in the acqui… (full text at CIViC) PMID 22194965 · Atefi et al., 2011 · Open in CIViC	civic
Vemurafenib	Cutaneous MelanomaALIAS	Predictive
NRAS Mutation14
Amuvatinib	Cutaneous MelanomaALIAS	Predictive	D	Supports Sensitivity Response	1	accepted	EID1476 Preclinical study in melanoma cell lines. Cell lines (2-5/assay) with NRAS mutation were more sensitive to Amuvatinib (inhibitor targets multiple tyrosine kinases) than BRAF mutant cell lines in growt… (full text at CIViC) PMID 24950457 · Fedorenko et al., 2014 · Open in CIViC	civic
Binimetinib	Cutaneous MelanomaALIAS	Predictive	B	Supports Sensitivity Response	2	accepted	EID1472 Phase II study in 71 patients with NRAS or BRAF V600 mutant melanoma treated with MEK162. Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed). PMID 23414587 · Ascierto et al., 2013 · Open in CIViC	civic
〃	Cutaneous MelanomaALIAS
NRAS Q615
Binimetinib	Cutaneous MelanomaALIAS	Predictive	B	Supports Sensitivity Response	2	accepted	EID1226 Phase 2 study of MEK162 in patients with advanced melanoma and NRAS or BRAF mutation. 71 patients were enrolled, 6/30 patients with NRAS mutation had a partial response (Gln61Leu 1 Patient, Gln61Lys 9… (full text at CIViC) PMID 23414587 · Ascierto et al., 2013 · Open in CIViC	civic
Selumetinib	Cutaneous MelanomaALIAS	Predictive	C	Supports Sensitivity Response	2	accepted	EID1473 Phase 1 trial in 57 patients with advanced cancers treated with selumetinib. 4 melanoma patients had NRAS Q61 mutations. One patient with NRAS mutation had 70% tumor shrinkage after three cycles of se… (full text at CIViC) PMID 18390968 · Adjei et al., 2008 · Open in CIViC	civic
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER
NRAS G12D2
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	—	accepted	EID3693 In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFO… (full text at CIViC) PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC	civic
Cetuximab + IrinotecanCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID2002 One patient participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS G12D and was wild type for KRAS, PIK3CA, and… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
NRAS Q179*1
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	—	accepted	EID4785 In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFO… (full text at CIViC) PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC	civic
NRAS Q61R3
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID2184 Five patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61R and were wildtype for KRAS, BRAF and P… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
Belvarafenib	Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID13220 A patient with melanoma harboring NRAS Q61R received belvarafenib monotherapy after one prior line of systemic therapy and achieved stable disease as the best RECIST response. At the October 2023 data… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic
Temozolomide	Melanoma	Predictive	C	Supports Sensitivity Response
NRAS G12C1
Cetuximab + ChemotherapyCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID3845 Two patients participating in a large retrospective trial of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS G12C and were wild type for KRAS, PIK3CA, an… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
NRAS Q61L3
Cetuximab + IrinotecanCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	3	accepted	EID2181 Two patients participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had tumors which harbored NRAS Q61L and were wildtype for KRAS, BRAF and PI… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
Temozolomide	Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID22 In a melanoma patient with NRAS Q61L mutation, treatment with temozolomide resulted in disease free survival of 14 months. PMID 21576590 · Soon et al., 2011 · Open in CIViC	civic
Belvarafenib	Mucosal Melanoma	Predictive	C	Supports Sensitivity Response
NRAS Q61H1
Cetuximab + IrinotecanCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID3690 One patient participating in a large retrospective study of cetuximab in metastatic, treatment refractory colorectal cancer had a tumor which harbored NRAS Q61H was wildtype for KRAS, BRAF and PIK3CA.… (full text at CIViC) PMID 20619739 · De Roock et al., 2010 · Open in CIViC	civic
BRAF V600E + HRAS Mutation + KRAS Mutation + NF1 Mutation + NRAS MutationHRAS BRAF NF1 KRAS NRAS1
Selumetinib	Malignant NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11681 In this phase II study of the arm E of the NCI-COG pediatric MATCH trial, 20 patients (median age: 14) were treated with Selumetinib. High-grade glioma (n=7) and rhabdomyosarcoma (n=7) were the most c… (full text at CIViC) PMID 35363510 · Eckstein et al., 2022 · Open in CIViC	civic
BRAF V600E + HRAS Mutation + KRAS Mutation + NF1 Inactivating Mutation + NRAS MutationHRAS NF1 BRAF KRAS NRAS1
Selumetinib	Malignant NeoplasmALIAS	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11696 In this Phase II study, 20 patients harboring activating RAS gene mutations (KRAS = 8, NRAS = 3. HRAS = 1), BRAF V600E mutations, and NF1 inactivating mutations (n=7) were treated with Selumetinib. No… (full text at CIViC) PMID 35363510 · Eckstein et al., 2022 · Open in CIViC	civic
NRAS G12A1
Belvarafenib	Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID13153 A patient with melanoma harboring NRAS G12A received belvarafenib monotherapy after two prior lines of systemic therapy and achieved a partial response as the best RECIST response. Belvarafenib treatm… (full text at CIViC) PMID 38470950 · Kim et al., 2024 · Open in CIViC	civic
NRAS Gain1
Binimetinib	Melanoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID6899 In melanoma preclinical models, increased NRAS expression enhanced sensitivity to binimetinib in NRAS-copy-normal A875 cells, whereas NRAS knockdown decreased binimetinib sensitivity in NRAS-gain WM26… (full text at CIViC) PMID 29245078 · Yan et al., 2018 · Open in CIViC	civic
NRAS G13D1
Tanespimycin	Melanoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID21 Likely due to increased reliance of mutant NRAS on HSP90 for stabilization, inhibition of HSP90 by 17-AAG was shown to be effective in a patient with metastatic malignant melanoma with an NRAS G13D mu… (full text at CIViC) PMID 18375819 · Banerji et al., 2008 · Open in CIViC	civic
BRAF V600E + NRAS MutationBRAF NRAS1
Dabrafenib + VemurafenibSubstitutes	Melanoma	Predictive	B	Supports Resistance	2	accepted	EID6263 In a retrospective study of 44 relapsed melanoma patients harboring BRAF V600E or V600K (known BRAF inhibitor sensitizing mutations), MAPK pathway reactivation mechanisms were implicated in acquired r… (full text at CIViC) PMID 24265155 · Shi et al., 2014 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (333)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

health-canada-dpdRegulatory46 approval records · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Temozolomide	CA Health Canada	—	Marketed in Canada as JAMP TEMOZOLOMIDE (DIN 02516810) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 25, 2022	health-canada-dpd
Temozolomide	CA Health Canada	—	Marketed in Canada as ACH-TEMOZOLOMIDE (DIN 02438119) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jan 13, 2016	health-canada-dpd
Temozolomide	CA Health Canada	—	Marketed in Canada as TEVA-TEMOZOLOMIDE (DIN 02441160) under ATC L01AX03 TEMOZOLOMIDE. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approved

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (349)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 188 recruiting · 62 active phase 3 · 1,723 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 51–100 of 349 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07291037	Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations(TROPION-Lung17)	recruiting	Phase 3	400	AstraZenecaINDUSTRY	21	Sep 4, 2026	clinicaltrials
NCT03178552	A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)(B-FAST)	active not recruiting	Phase 2 / Phase 3	1,000	Hoffmann-La RocheINDUSTRY	27	Sep 3, 2026	clinicaltrials
NCT04657991	A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma	active not recruiting	Phase 3	257	PfizerINDUSTRY	27	Sep 3, 2026	clinicaltrials
NCT05673148	Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial	recruiting	Phase 2	146	Alliance for Clinical Trials in OncologyOTHER	2	Sep 3, 2026	clinicaltrials
NCT06252649	Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation(CodeBreaK 301)	recruiting	Phase 3	450	AmgenINDUSTRY	35	Sep 3, 2026	clinicaltrials
NCT06541262	Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors	recruiting	Phase 1 / Phase 2	104	Milton S. Hershey Medical CenterOTHER	2	Sep 3, 2026	clinicaltrials
NCT06632327	Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer	active not recruiting	Phase 3	37	Alliance for Clinical Trials in OncologyOTHER	1	Sep 2, 2026	clinicaltrials
NCT07216105	FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors	recruiting	Phase 1	119	Fate TherapeuticsINDUSTRY	1	Sep 2, 2026	clinicaltrials
NCT07252739	KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)	recruiting	Phase 2	140	Merck Sharp & Dohme LLCINDUSTRY	13	Sep 2, 2026	clinicaltrials
NCT07293247	A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment	recruiting	Phase 2	164	Alliance for Clinical Trials in OncologyOTHER	1	Sep 2, 2026	clinicaltrials
NCT07363408	Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer	not yet recruiting	Phase 1	30	City of Hope Medical CenterOTHER	1	Sep 2, 2026	clinicaltrials
NCT04557956	Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	active not recruiting	Phase 1 / Phase 2	16	National Cancer Institute (NCI)NIH	1	Sep 1, 2026	clinicaltrials
NCT04570423	A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy	recruiting	Phase 2	40	Spectrum Pharmaceuticals, IncINDUSTRY	1	Sep 1, 2026	clinicaltrials
NCT05355701	A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.	active not recruiting	Phase 1	103	PfizerINDUSTRY	3	Sep 1, 2026	clinicaltrials
NCT07070440	DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)	recruiting	Phase 1 / Phase 2	180	Dizal PharmaceuticalsINDUSTRY	1	Aug 31, 2026	clinicaltrials
NCT02152995	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer	active not recruiting	Phase 2	34	National Cancer Institute (NCI)NIH	1	Aug 28, 2026	clinicaltrials
NCT02224781	Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	active not recruiting	Phase 3	267	National Cancer Institute (NCI)NIH	1	Aug 28, 2026	clinicaltrials
NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	Phase 2	6,452	National Cancer Institute (NCI)NIH	3	Aug 28, 2026	clinicaltrials
NCT04449874	A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation	active not recruiting	Phase 1	498	Genentech, Inc.INDUSTRY	17	Aug 28, 2026	clinicaltrials
NCT06528496	N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma	recruiting	Phase 2	45	Memorial Sloan Kettering Cancer CenterOTHER	1	Aug 28, 2026	clinicaltrials
NCT06682780	A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours	recruiting	Phase 1 / Phase 2	320	LaNova Medicines LimitedINDUSTRY	1	Aug 28, 2026	clinicaltrials
NCT06783647	A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]	recruiting	Phase 2	250	Nanjing Leads Biolabs Co.,LtdINDUSTRY	1	Aug 27, 2026	clinicaltrials
NCT06881784	Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)(RASolve 301)	recruiting	Phase 3	590	Revolution Medicines, Inc.INDUSTRY	19	Aug 27, 2026	clinicaltrials
NCT07474727	A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer	recruiting	Phase 2	180	Multitude Therapeutics Inc.INDUSTRY	1	Aug 27, 2026	clinicaltrials
NCT07790510	HSK42360-Na Tablets Combined With Cetuximab With or Without Chemotherapy in BRAF V600-Mutant Metastatic Colorectal Cancer	recruiting	Phase 1 / Phase 2	180	Haisco Pharmaceutical Group Co., Ltd.INDUSTRY	1	Aug 27, 2026	clinicaltrials
NCT04025879	A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer	active not recruiting	Phase 3	461	Bristol-Myers SquibbINDUSTRY	22	Aug 26, 2026	clinicaltrials
NCT04329494	PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer	recruiting	Phase 1	49	City of Hope Medical CenterOTHER	1	Aug 26, 2026	clinicaltrials
NCT04656652	Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)	active not recruiting	Phase 3	605	Daiichi SankyoINDUSTRY	26	Aug 26, 2026	clinicaltrials
NCT06818812	A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	active not recruiting	Phase 1	30	Incyte CorporationINDUSTRY	1	Aug 25, 2026	clinicaltrials
NCT00463814	AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies	active not recruiting	Phase 1	58	AstraZenecaINDUSTRY	3	Aug 24, 2026	clinicaltrials
NCT02858921	Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma(Neo Trio)	active not recruiting	Phase 2	60	Melanoma Institute AustraliaOTHER	1	Aug 24, 2026	clinicaltrials
NCT06586515	MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors(MOONRAY-01)	recruiting	Phase 1	630	Eli Lilly and CompanyINDUSTRY	9	Aug 24, 2026	clinicaltrials
NCT06803680	A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors	recruiting	Phase 1	90	BeOne MedicinesINDUSTRY	3	Aug 24, 2026	clinicaltrials
NCT04535401	Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines	active not recruiting	Phase 1	10	National Cancer Institute (NCI)NIH	1	Aug 21, 2026	clinicaltrials
NCT07209111	A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)(KANDLELIT-014)	recruiting	Phase 2	150	Merck Sharp & Dohme LLCINDUSTRY	19	Aug 21, 2026	clinicaltrials
NCT04008030	A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)(CheckMate 8HW)	active not recruiting	Phase 3	839	Bristol-Myers SquibbINDUSTRY	24	Aug 20, 2026	clinicaltrials
NCT06741644	A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors	recruiting	Phase 1 / Phase 2	800	CStone PharmaceuticalsINDUSTRY	3	Aug 20, 2026	clinicaltrials
NCT04598009	Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma	recruiting	Phase 2	25	University of California, San FranciscoOTHER	1	Aug 18, 2026	clinicaltrials
NCT06743126	SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma(SUPRAME)	recruiting	Phase 3	360	Immatics US, Inc.INDUSTRY	6	Aug 18, 2026	clinicaltrials
NCT04895709	A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors	recruiting	Phase 1 / Phase 2	1,109	Bristol-Myers SquibbINDUSTRY	8	Aug 17, 2026	clinicaltrials
NCT07440290	DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE)	recruiting	Phase 2 / Phase 3	30	Cancer Research UKOTHER	1	Aug 17, 2026	clinicaltrials
NCT05722327	Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer	active not recruiting	Phase 1	24	M.D. Anderson Cancer CenterOTHER	1	Aug 14, 2026	clinicaltrials
NCT06074588	Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)	active not recruiting	Phase 3	556	Merck Sharp & Dohme LLCINDUSTRY	25	Aug 14, 2026	clinicaltrials
NCT05671510	ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors(PRESERVE-003)	active not recruiting	Phase 3	630	OncoC4, Inc.INDUSTRY	12	Aug 13, 2026	clinicaltrials
NCT06120075	A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies(ARC-27)	active not recruiting	Phase 1	91	Arcus Biosciences, Inc.INDUSTRY	1	Aug 13, 2026	clinicaltrials
NCT06797336	A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors	recruiting	Phase 1	240	PAQ Therapeutics, Inc.INDUSTRY	2	Aug 12, 2026	clinicaltrials
NCT07372625	A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.	recruiting	Phase 1	14	PMV Pharmaceuticals, IncINDUSTRY	1	Aug 12, 2026	clinicaltrials
NCT01989585	Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma	active not recruiting	Phase 1 / Phase 2	75	National Cancer Institute (NCI)NIH	1	Aug 11, 2026	clinicaltrials
NCT03392246	A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer	active not recruiting	Phase 2	25	Dana-Farber Cancer InstituteOTHER	1	Aug 11, 2026	clinicaltrials
NCT04526782	ENCOrafenib With Binimetinib in bRAF NSCLC(ENCO-BRAF)	active not recruiting	Phase 2	119	Intergroupe Francophone de Cancerologie ThoraciqueOTHER	1	Aug 11, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (13)

Drugs with predictive evidence (20)

Predictive evidence items (47)

Approvals mentioning the linked drugs (333)

Active trials (349)

Linked publications (37)